AstraZeneca is heavily investing in cancer-fighting technology with a significant manufacturing expansion in Asia

Company plans to build a $1.5 billion ADC manufacturing facility in Singapore, British pharma’s first site for end-to-end ADC production.

The site will encompass all stages of the ADC manufacturing process at commercial scale, from antibody and chemotherapy production to drug-linker conjugation

The facility will receive support from Singapore’s Economic Development Board (EDB)